NCT06239727 2026-03-06
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06976190 2026-01-20
Magic-C002
Shanghai Miracogen Inc.
Phase 3 Recruiting
NCT07158164 2025-11-13
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
Phase 4 Recruiting
NCT06494995 2025-06-04
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Fudan University
Phase 2 Recruiting
NCT06629597 2025-02-10
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT06277050 2024-04-30
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 3 Recruiting
NCT06259721 2024-03-07
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 2 Recruiting
NCT05514275 2022-08-24
Radiotherapy Combined With Endostatin and Capecitabine for NPC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT05342792 2022-04-25
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT05290194 2022-04-14
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2 Recruiting
NCT05044117 2022-03-03
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
Sun Yat-sen University
Phase 3 Recruiting